Vitamin D administration leads to a shift of the intestinal bacterial composition in Crohn’s disease patients, but not in healthy controls
Laen...
Kuupäev
2018
Kättesaadav alates
Ajakirja pealkiri
Ajakirja ISSN
Köite pealkiri
Kirjastaja
Wiley
Abstrakt
OBJECTIVE: Dysbiosis is a common feature in the
pathogenesis of inflammatory bowel diseases (IBD).
Environmental factors, such as vitamin D deficiency,
seem to play a role in the intestinal inflammation of
IBD. The aim of this study was to investigate whether
vitamin D administration has an impact on the bacterial
composition in Crohn’s disease (CD) compared
to healthy controls (HC).
METHODS: A prospective, longitudinal, controlled
interventional analysis was conducted in seven
patients with CD in clinical remission and 10 HC to
investigate the effect of orally administrated vitamin
D on the intestinal bacterial composition using 16S
ribosomal RNA gene amplicon sequencing. Clinical
parameters were assessed.
RESULTS: In contrast to HC, microbial communities
of CD patients changed significantly during early
vitamin D administration. However, a further
increase in vitamin D level was associated with a
reversal of this effect and additionally with a decrease
in the bacterial richness in the CD microbiome. Specific
species with a high abundancy were found during
vitamin D administration in CD, but not in HC;
the abundancy of Alistipes, Barnesiella, unclassified
Porphyromonadaceae (both Actinobacteria), Roseburia,
Anaerotruncus, Subdoligranulum and an unclassified
Ruminococaceae (all Firmicutes) increased
significantly after 1-week vitamin D administration
in CD.
CONCLUSIONS: Vitamin D has a specific influence
on the bacterial communities in CD, but not in
HC. Administration of vitamin D may have a positive
effect in CD by modulating the intestinal bacterial
composition and also by increasing the abundance of
potential beneficial bacterial strains.
The authors would like to thank Jana NORMANN for excellent technical assistance and the SILVA_NGS team for bioinformatic support. Purchase of the Illumina MiSeq was kindly supported by the EU-EFRE (European Funds for Regional Development) program and funds from the University Medicine Rostock. H.S. received a research grant from the Damp Foundation (2016–04). The study was registered in the German Clinical Trials Register (Registration number DRKS00013485).
The authors would like to thank Jana NORMANN for excellent technical assistance and the SILVA_NGS team for bioinformatic support. Purchase of the Illumina MiSeq was kindly supported by the EU-EFRE (European Funds for Regional Development) program and funds from the University Medicine Rostock. H.S. received a research grant from the Damp Foundation (2016–04). The study was registered in the German Clinical Trials Register (Registration number DRKS00013485).
Kirjeldus
Märksõnad
Crohn disease, inflammatory bowel diseases, microbiota, vitamin D, articles